ArticleOpen medicine (Warsaw, Poland)2026
Systematic pan-cancer analysis identifies PIK3R3 as a lipid metabolism and immune regulation prognostic biomarker.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to explore the critical role of PIK3R3 in pan-cancer, which to facilitate the development of more targeted prognostic markers and therapeutic strategies for these malignancies. Methods: In our study, pan-cancer transcriptome datasets were retrieved from Xena database. Subsequently, utilizing the Wilcoxon test, univariate Cox regression analysis as well as Kaplan-Meier (K-M) survival analysis to identify cancer types with high relevance to PIK3R3. Clinical metadata were stratified for correlation analysis, followed by differential expression gene (DEG) identification, overrepresentation analysis, and various functional analysis methods. Results: Lower-grade glioma (LGG), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and uterine corpus endometrial carcinoma (UCEC) exhibited strong associations with PIK3R3. PIK3R3 was closely linked to tumor grade stratification in LGG and UCEC and likely regulated these cancers via pathways such as lipid metabolism. Notably, UCEC showed high-level PIK3R3 mutations, mainly involving mutation and amplification. Compounds including Tetrachlorodibenzodioxin (TCDD), 1-Methyl-4-phenylpyridinium (MPP+), Estradiol, and Valproic Acid were predicted to target PIK3R3. Conclusions: Our results provide novel insights into the molecular mechanisms underlying PIK3R3-associated tumorigenesis and progression, which may contribute to the development of more targeted prognosis markers and therapeutic strategies for these malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.